Conavi Medical Annual General & Special Meeting of Shareholders

Information Circular
Form of Proxy
Notice & Access
Annual Financial Statements
MD&A

The annual general and special meeting of the shareholders of Conavi Medical Corp. will be held electronically on March 31, 2026 at 10:00am EST. Registered Shareholders and duly appointed proxyholders can attend the Meeting via webcast by clicking below:

Meeting Link
Virtual Summit User Guide

The Novasight Hybrid System is intended for intravascular imaging of coronary arteries and is indicated in patients who are candidates for transluminal interventional procedures. The Novasight Hybrid System is cleared for sale in the following jurisdictions (regulatory approvals referenced): • United States: FDA 510(k) clearance (K172258) • Canada: Health Canada medical device license (102500) • Japan: PMDA medical device license (catheter: 30200BZX00040000, console + PIM: 30200BZX00039000) ISI: conavi.com/novasight/isi